Candriam S.C.A. Sells 483 Shares of Amgen Inc. $AMGN

Candriam S.C.A. reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% in the second quarter, Holdings Channel.com reports. The fund owned 505,720 shares of the medical research company’s stock after selling 483 shares during the quarter. Amgen comprises about 0.8% of Candriam S.C.A.’s portfolio, making the stock its 21st largest holding. Candriam S.C.A.’s holdings in Amgen were worth $141,208,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of AMGN. Fairvoy Private Wealth LLC lifted its position in shares of Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock worth $885,000 after purchasing an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC increased its stake in Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after buying an additional 35 shares during the period. Crumly & Associates Inc. lifted its holdings in Amgen by 3.2% during the 2nd quarter. Crumly & Associates Inc. now owns 1,146 shares of the medical research company’s stock valued at $320,000 after buying an additional 36 shares in the last quarter. Maryland Capital Advisors Inc. lifted its holdings in Amgen by 5.2% during the 2nd quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company’s stock valued at $204,000 after buying an additional 36 shares in the last quarter. Finally, Lion Street Advisors LLC boosted its position in Amgen by 1.3% in the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company’s stock valued at $774,000 after buying an additional 36 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research analyst reports. DZ Bank lifted their price target on shares of Amgen from $335.00 to $364.00 in a research note on Monday. Cantor Fitzgerald lifted their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Morgan Stanley dropped their target price on shares of Amgen from $333.00 to $329.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 5th. Bank of America raised their target price on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Finally, Raymond James Financial assumed coverage on shares of Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $307.94.

Amgen Price Performance

AMGN opened at $336.28 on Thursday. The firm has a market capitalization of $181.08 billion, a PE ratio of 27.50, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The business’s 50-day moving average is $292.73 and its two-hundred day moving average is $289.69. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $342.40.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the business earned $5.58 EPS. The company’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 2.8%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is 73.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.